DCI Urges Priority Access to COVID-19 Vaccines for Cancer Patients & Survivors
Today, Duke Cancer Institute joined a broad spectrum of organizations representing laboratory, translational, and clinical researchers; other health care professionals; patients with cancer; and patient advocates in sending a letter to the Biden administration and other public health officials that highlights the importance of prioritizing patients with active cancer and survivors of cancer when administering COVID-19 vaccines. Cancer puts individuals at high risk for severe illness and death from COVID-19.
AACR PRESS RELEASE: 130 Organizations, Cancer Centers, and Other Institutions Send Letter to Biden Urging Priority Access to a COVID-19 Vaccine for Cancer Patients and Survivors
WASHINGTON, D.C. – Today, 130 organizations, cancer centers, and other institutions sent a letter to President Joseph R. Biden, key members of his administration, and leading public health officials at state health departments to underscore the importance of prioritizing patients with active cancer and survivors of cancer when administering the lifesaving COVID-19 vaccines.The broad spectrum of cosignatories to this letter represent laboratory, translational, and clinical researchers; other health care professionals; millions of patients with cancer and survivors of cancer; and patient advocates from across the United States.
Recent research has shown that patients with cancer are at increased risk of severe illness and death if they are infected with the virus. Moreover, patients with cancer often receive frequent in-person care, which increases their risk of exposure to the virus. Certain survivors of cancer also have a higher probability of infection and COVID-19-related death compared to the general population.
While the Centers for Disease Control and Prevention recognizes that cancer places individuals at higher risk for severe COVID-19, many states are broadening and simplifying the groups eligible for COVID-19 vaccination to speed up distribution of the vaccines. The letter notes that while widespread, rapid vaccination is a worthy goal, the currently limited supply of vaccines means that many who are at high risk for severe illness and death from COVID-19, including patients with active cancer and survivors of cancer, may continue to wait for many months if they are not provided with priority access.
The letter, initiated by the American Association for Cancer Research (AACR), urges the Biden administration and public health officials at the state level to prioritize patients with cancer and survivors of cancer in statewide vaccination plans. Read the full letter here or below
Letter to President Biden and Leaders of State Public Health Departments: Prioritizing COVID-19 Vaccines for Patients with Cancer and Survivors of Cancer
February 17, 2021
President Joseph R. Biden, Jr.
The White House
1600 Pennsylvania Avenue,NW
Washington, DC 20500
Dear Mr. President,
On behalf of a broad spectrum of organizations, cancer centers, and other institutions that represent laboratory, translational, and clinical researchers; other health care professionals; millions of patients with cancer and survivors of cancer; and patient advocates, we are writing today to thank you for your extraordinary commitment to conquering cancer and to applaud your determined focus to end the COVID-19 pandemic.
Cancer is a collection of diseases that kills more than 600,000 Americans each year, making it the second leading cause of death in the U.S. There are also more than 17 million survivors of cancer in the U.S., many of whom are at a higher risk of dying from COVID-19. Therefore, we are asking for your assistance in ensuring that patients with active cancer and survivors of cancer are prioritized to receive a COVID-19 vaccine.
We fully support your COVID-19 vaccination plan that calls for broadening access and vaccinating as many Americans as rapidly as possible. However, we are compelled to underscore the urgency of prioritizing access to a COVID-19 vaccine for patients with active cancer and survivors of cancer.
There is mounting evidence that patients with cancer are at increased risk of severe illness and death if they are infected with the virus. In December 2020, an article published in the Journal of the American Medical Association presented data showing that patients with cancer who are diagnosed with COVID-19 are more likely to require hospitalization (47.46%) than persons without cancer who have been diagnosed with COVID-19 (24.26%).1 Also, the AACR COVID-19 and Cancer Task Force recently published an article in the AACR journal Cancer Discovery that reviewed the available literature since the onset of the pandemic (28 peer-reviewed articles) on fatality rates of patients with cancer who developed COVID-19;2 these data have shown that COVID-19 fatality rates for patients with cancer were double that of patients without cancer.
Additionally, as noted by the Cancer Leadership Council,3 a patient-centered forum of
national advocacy organizations addressing public policies related to cancer, as well as other recent studies, certain survivors of cancer have a higher probability of infection and COVID-19-related death compared to the general population.1,3–5 Further, the Council stressed that the risks are even greater for patients with active cancer.
We also know that many Americans are delaying regular doctor appointments that could lead to a diagnosis of cancer, meaning that we are likely to see a higher number of patients diagnosed when their cancers are at a more advanced stage. Without the protection offered by a vaccine, these patients are not only at risk of being infected with COVID-19, but a COVID-19 diagnosis could also severely impact their available treatment options.
Patients with cancer who are in treatment often receive frequent in-person clinical care, which has the potential to increase their risk of exposure to the virus. Furthermore, certain patients with cancer are vulnerable to infection because of their weakened immune status, which is attributable to their cancers and/or their treatments.6 Clearly, vaccinating patients with cancer who are in treatment offers the best protection against the threat of contracting the virus.
On January 22, 2021, the Vaccination Advisory Committee of the National Comprehensive Cancer Network, an alliance of 30 leading U.S. cancer centers that publishes clinical practice guidelines in oncology, recommended that patients with active cancer as well as their caregivers and household contacts should all be prioritized for COVID-19 vaccination.7,8
At the January 27, 2021 meeting of the CDC Advisory Committee on Immunization Practices, it was reported that certain states in the U.S. are prioritizing patients with active cancer and survivors of cancer in a number of ways. As a result, we want to again emphasize the importance of ensuring that prioritization of vaccine supplies be given to high-risk populations that include patients with active cancer and survivors of cancer.
In closing, for the reasons stated above, we sincerely hope that you and your colleagues in the administration will stress to all State Public Health Departments that patients
with active cancer and survivors of cancer must be provided priority access to a lifesaving COVID-19 vaccine.
If you have questions or require further information about this issue, please contact the American Association for Cancer Research (email@example.com).
Thank you again for your leadership. We stand ready to work with you and your administration on this critically important issue.
Abramson Cancer Center at the University of Pennsylvania
American Association for Cancer Research
American Brain Tumor Association
American Cancer Society Cancer Action Network, Inc.
American Liver Foundation
American Radium Society
American Society for Radiation Oncology
American Society of Hematology
ArmorUp for Life
Association for Clinical Oncology
Association of American Cancer Institutes
Ben & Catherine Ivy Foundation
Blue Hat Foundation
Boston University – Boston Medical Center Cancer Center
Breast Cancer Research Foundation
Cancer Center at Brown University
Cancer Center at Illinois
Cancer Forum of the American Public Health Association
Cancer Support Community
Cardinal Bernardin Cancer Center, Stritch School of Medicine Loyola University Chicago
Case Comprehensive Cancer Center at Case Western Reserve University
Chao Family Comprehensive Cancer Center at The University of California Irvine
Children’s Cancer Cause
Chris Draft Family Foundation
City of Hope
Cleveland Clinic Taussig Cancer Institute
Cold Spring Harbor Laboratory Cancer Center
Colorectal Cancer Alliance
Columbia University Herbert Irving Comprehensive Cancer Center
Community Oncology Alliance
Cure Breast Cancer Foundation
Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine
Dana-Farber Cancer Institute
Deadliest Cancers Coalition
Debbie’s Dream Foundation
Duke Cancer Institute
- Wang, Q.; Berger, N. A.; Xu, R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2020, E1–E8. https://doi.org/10.1001/jamaoncol.2020.6178
- Ribas, A.; Sengupta, R.; Locke, T.; Zaidi, S. K.; Campbell, K. M.; Carethers, J. M.; Jaffee, E. M.; Wherry, E. J.; Soria, J.-C.; D’Souza, G. Priority COVID-19 Vaccination for Patients with Cancer While Vaccine Supply Is Limited. Cancer Discov. 2021, 11 (2), 233–236. https://doi.org/10.1158/2159-8290.CD-20-1817
- Cancer Leadership Council. Letter to CDC ACIP on Prioritizing COVID-19 Vaccinations for Patients with Cancer. 2021. https://canceradvocacy.org/wp-content/uploads/CLC-to-ACIP-re-Covid-vaccines-cancer-patients-Jan-2021.pdf
- Sng, C. C. T.; Wong, Y. N. S.; Wu, A.; Ottaviani, D.; Chopra, N.; Galazi, M.; Benafif, S.; Soosaipillai, G.; Roylance, R.; Lee, A. J. X.; Shaw, H. Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience. Front. Oncol. 2020, 10. https://doi.org/10.3389/fonc.2020.595804
- Williamson, E. J.; Walker, A. J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C. E.; Curtis, H. J.; Mehrkar, A.; Evans, D.; Inglesby, P.; Cockburn, J.; McDonald, H. I.; MacKenna, B.; Tomlinson, L.; Douglas, I. J.; Rentsch, C. T.; Mathur, R.; Wong, A. Y. S.; Grieve, R.; Harrison, D.; Forbes, H.; Schultze, A.; Croker, R.; Parry, J.; Hester, F.; Harper, S.; Perera, R.; Evans, S. J. W.; Smeeth, L.; Goldacre, B. Factors Associated with COVID-19-Related Death Using OpenSAFELY. Nature 2020, 584 (7821), 430–436. https://doi.org/10.1038/s41586-020-2521-4
- American Cancer Society. Why People with Cancer Are More Likely to Get Infections. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/why-people-with-cancer-are-at-risk.html (accessed Feb 5, 2021).
- Pergam, S.; Baden, L.; Abel, G.; Bunnell, C.; Cinar, P.; Hamdan, A.; Khushalani, N.; Narayana, S.; Papadopoulos, E.; Riely, G.; Saullo, J.; Segal, B.; Tabor, H.; Tan, T.; Zimmer, A.; Carlson, R.; Koh, W.-J. Preliminary Recommendations of the NCCN COVID-19 Vaccination Advisory Committee. 2021, National Comprehensive Cancer Network. https://www.nccn.org/covid-19/pdf/COVID-19_Vaccination_Guidance_V1.0.pdf
- Cohen, S. Experts Recommend People with Cancer be Prioritized for a COVID-19 Vaccine. https://connect.uclahealth.org/2021/01/25/experts-recommend-people-with-cancer-be-prioritized-for-the-covid-19-vaccine/ (accessed Feb 5, 2021).